14. Chronic inflammatory demyelinating polyneuropathy Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 175 / Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24
Drugs and their primary sponsors and trial info
: immunoglobulina umana normale per somministrazione endovenosa
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom;
ARGX-113
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 2 EUCTR2019-003107-35-PL Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-NL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-HU Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-ES Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-BG Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
ARGX-117
argenx
2022 Phase 2 NCT05225675 United States;
ARGX-117 IV
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
argenx BV
2022 Phase 2 EUCTR2021-003302-50-NL Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2022 Phase 2 EUCTR2021-003302-50-ES Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Albumin (Human) , United States Pharmacopeia (USP)
Grifols Therapeutics Inc.
2004 Phase 3 NCT00220740 Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States;
Anti-C5 antibody
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom;
Anti-Thymocyte Globulin
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Autologous Hematopoietic Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
BIVV020
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2020-004006-54-IT Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-NL France;Germany;Italy;Netherlands;Poland;
2021 Phase 2 EUCTR2020-004006-54-FR France;Netherlands;
2021 Phase 2 EUCTR2020-004006-54-DE France;Germany;Italy;Netherlands;Poland;
BIVV020/SAR445088
Bioverativ, a Sanofi company
2021 Phase 2 NCT04658472 Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United States;
Carmustine
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Cyclophosphamide
Stony Brook University
2003 Phase 2 NCT01236456 United States;
Cytarabine
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Dexamethasone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom;
Eculizumab
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom;
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
argenx
2020 Phase 2 NCT04280718 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-PL Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-NL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-HU Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-DK Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-DE Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-BG Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-BE Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-ES Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-DE Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-BG Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Efgartigimod PH20 SC in stage B
argenx
2020 Phase 2 NCT04281472 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Efgartigimod alfa
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 2 EUCTR2019-003107-35-PL Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-NL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-HU Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-ES Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Etoposide
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
FINGOLIMOD HYDROCHLORIDE
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
FTY720
Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-JapicCTI-121961 -
FTY720I
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Fampyra
Department of Neurology, Odense University Hospital
2020 Phase 2 EUCTR2020-002438-34-DK Denmark;
Fibrinogen concentrate
University Medical Centre Ljubljana
2018 - NCT03801135 Slovenia;
Fingolimod
Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-JapicCTI-121961 -
Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS)
Teijin Pharma Limited
2014 Phase 3 JPRN-JapicCTI-142472 Japan;
2014 Phase 3 JPRN-JapicCTI-142471 Japan;
GILENYA 0,5 mg cápsulas duras
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Gammanorm
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark;
Gilenya
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Group C meningococcal conjugate vaccine
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
H.P. Acthar® Gel
Mamatha Pasnoor, MD
2015 Phase 2 NCT02574962 United States;
HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
HIDROCLORURO DE FINGOLIMOD
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
HUMAN NORMAL IMMUNOGLOBULIN (IV)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark;
CSL Behring GmbH
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland;
2010 - EUCTR2009-017672-24-FI Finland;
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
Haemophilus type b vaccine (conjugated)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Hematopoietic stem cell transplantation
Northwestern University
2005 Phase 2 NCT00278629 United States;
Hizentra
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark;
2013 Phase 2 EUCTR2013-001428-20-DK Denmark;
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark;
CSL Behring
2022 - NCT04672733 France;
Hizentra®
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin (IVIg)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Human normal immunoglobulin (SCIg)
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin G (IgG > purity)
CSL Behring GmbH
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland;
2010 - EUCTR2009-017672-24-FI Finland;
Human normal immunoglobulin for intravenous administration
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
Human normal immunoglobulin for intravenous administrationn
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
Hyqvia
UMC Utrecht
2016 Phase 3 EUCTR2015-000828-28-NL Netherlands;
I10
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
I10E
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom;
IGIV,
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark;
IGVENA*FL 200ML 10G+SET
KEDRION
2007 - EUCTR2005-001136-76-IT Italy;
IMMUNOGLOBULIN G
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom;
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom;
IQYMUNE
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
IgPro10
CSL Behring
2019 Phase 4 NCT03684018 Canada;United States;
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
IgPro20
CSL Behring
2014 Phase 3 NCT02027701 Australia;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
IgPro20 (high dose)
CSL Behring
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
IgPro20 (low dose)
CSL Behring
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Immune Globulin IV (Human), Caprylate/Chromatography Purified
Grifols Therapeutics Inc.
2004 Phase 3 NCT00220740 Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States;
Immune Globulin Intravenous (human),
Baxalta now part of Shire
2008 Phase 3 NCT00666263 Canada;Denmark;Netherlands;Poland;United States;
Immune Globulin Intravenous Solution
Vera Bril
2017 Phase 3 NCT03166527 Canada;
Immune Globulin Subcutaneous (Human)
University of South Florida
2014 - NCT02465359 United States;
Immune globulin
National Center for Research Resources (NCRR)
1992 Phase 3 NCT00004772 -
Immunoadsorption
University of Ulm
2022 Phase 2 NCT04881682 Germany;
Immunoglobulin
University of Aarhus
2020 Phase 4 NCT04589299 Denmark;
Immunoglobulin perfusion
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France;
Immunoglobuline G
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic;
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine;
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania;
Immunoglobulins
Rigshospitalet, Denmark
2014 - NCT02111590 Denmark;
University of Ulm
2022 Phase 2 NCT04881682 Germany;
Immunoglobulins, normal human, for extravascular adm.
CSL Behring AG
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom;
Immunoglobulins, normal human, for intravascular adm.
KEDRION
2007 - EUCTR2005-001136-76-IT Italy;
Intratect
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Intravenous Immunoglobulin
University of Minnesota
2015 - NCT02414490 United States;
Intravenous immunoglobulin
University of Aarhus
2005 Phase 2 NCT00268788 Denmark;
Intravenous immunoglobulin (IVIg)
National Institute of Neurological Disorders and Stroke (NINDS)
1990 Phase 2 NCT00001287 United States;
J07AH07
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
KIOVIG
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
KIOVIG 100 mg/ml solution for infusion
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark;
Kiovig
Erasmus MC
2014 Phase 4 EUCTR2013-004988-32-NL Netherlands;
Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom;
Lipoic acid
Oregon Health and Science University
2009 Phase 2 NCT00962429 United States;
MABTHERA - 1 FIALA 500 MG 50 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
2018 Phase 2 EUCTR2018-001347-31-IT Italy;
MD1003
MedDay Pharmaceuticals SA
2016 Phase 2 NCT02967679 France;
Melphalan
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Menjugate
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Methylprednisolon (Solu-Medrol)
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;
Methylprednisolone
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom;
Methylprednisolone (Solu-Medrol)
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;
N. MENINGITIDIS GROUP C POLYSACCHARIDE
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
NPB-01
Nihon Pharmaceutical Co., Ltd
2013 Phase 3 NCT01827072 Japan;
2013 Phase 3 NCT01824251 Japan;
NewGam
Octapharma
2017 Phase 3 NCT02638207 Australia;Bulgaria;Canada;Czechia;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic;
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine;
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania;
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
PANZYGA
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
Panzyga
Octapharma
2022 Phase 3 NCT04929236 -
Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Placebo
Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-JapicCTI-121961 -
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Prednisolone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom;
Prednisone
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France;
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Prevenar 13 sospensione per iniezione
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Privigen
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark;
2013 Phase 2 EUCTR2013-001428-20-DK Denmark;
Privigen®
CSL Behring GmbH
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland;
2010 - EUCTR2009-017672-24-FI Finland;
RHuPH20
UMC Utrecht
2016 - NCT02885259 Netherlands;
RVG 51680
Department of Neurology, Academic Medical Center
2014 - EUCTR2013-005363-52-NL Netherlands;
RVG 56083
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;
Recombinant human hyaluronidase
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 Japan;
Rituximab
Iijima Masahiro
2021 Phase 2 JPRN-jRCTs041210046 Japan;
2019 Phase 2 JPRN-jRCT2041180037 Japan;
Nagoya University Hospital
2019 Phase 2 JPRN-UMIN000035753 Japan;
University of Kansas Medical Center
2022 Phase 2 NCT04480450 -
Rituximab (genetical recombination)
Nagoya University
2019 Phase 2 NCT03864185 Japan;
Rozanolixizumab
UCB Biopharma S.P.R.L.
2019 Phase 2 NCT03861481 Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
UCB Biopharma SRL
2020 - NCT05014724 -
2019 Phase 2 NCT04051944 Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
SAR445088 (formerly BIVV020)
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-PL France;Germany;Italy;Netherlands;Poland;
SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
Sodium chloride
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom;
Subcutaneous immunoglobulin
University of Aarhus
2005 Phase 2 NCT00268788 Denmark;
Subcuvia
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark;
Johannes Jakobsen
2016 Phase 2 NCT02556437 Denmark;
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark;
Syngeneic Bone Marrow Transplantation
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
TAK-771
Takeda
2021 Phase 3 NCT05084053 Japan;
TRIMETON - 10 MG/1 ML SOLUZIONE INIETTABILE 5 FIALE 1 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
UCB7665
UCB Biopharma SPRL
2020 Phase 2 EUCTR2018-004392-12-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2018-004392-12-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
UCB Biopharma SRL
2019 Phase 2 EUCTR2018-004392-12-BE Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
VACCINO PNEUMOCOCCICO SACCARIDICO
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Vivaglobin
CSL Behring
2007 Phase 2 NCT00701662 Germany;Italy;Switzerland;United Kingdom;
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom;
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom;
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom;
intravenous immunoglobulin (IVIg)
University of Toronto
2015 Phase 4 NCT02372149 Canada;
liquid formulation of human immunoglobulin
CSL Behring
2010 Phase 3 NCT01184846 Belgium;Finland;France;Germany;Poland;
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom;
ARGX-113
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 2 EUCTR2019-003107-35-PL Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-NL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-HU Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-ES Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-BG Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
ARGX-117
argenx
2022 Phase 2 NCT05225675 United States;
ARGX-117 IV
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
argenx BV
2022 Phase 2 EUCTR2021-003302-50-NL Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2022 Phase 2 EUCTR2021-003302-50-ES Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Albumin (Human) , United States Pharmacopeia (USP)
Grifols Therapeutics Inc.
2004 Phase 3 NCT00220740 Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States;
Anti-C5 antibody
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom;
Anti-Thymocyte Globulin
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Autologous Hematopoietic Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
BIVV020
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2020-004006-54-IT Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-NL France;Germany;Italy;Netherlands;Poland;
2021 Phase 2 EUCTR2020-004006-54-FR France;Netherlands;
2021 Phase 2 EUCTR2020-004006-54-DE France;Germany;Italy;Netherlands;Poland;
BIVV020/SAR445088
Bioverativ, a Sanofi company
2021 Phase 2 NCT04658472 Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United States;
Carmustine
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Cyclophosphamide
Stony Brook University
2003 Phase 2 NCT01236456 United States;
Cytarabine
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Dexamethasone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom;
Eculizumab
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom;
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
argenx
2020 Phase 2 NCT04280718 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-PL Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-NL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-HU Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-DK Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-DE Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-BG Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-BE Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-ES Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-DE Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-BG Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Efgartigimod PH20 SC in stage B
argenx
2020 Phase 2 NCT04281472 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Efgartigimod alfa
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
argenx BVBA
2020 Phase 2 EUCTR2019-003107-35-PL Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-NL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-HU Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-ES Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Etoposide
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
FINGOLIMOD HYDROCHLORIDE
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
FTY720
Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-JapicCTI-121961 -
FTY720I
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Fampyra
Department of Neurology, Odense University Hospital
2020 Phase 2 EUCTR2020-002438-34-DK Denmark;
Fibrinogen concentrate
University Medical Centre Ljubljana
2018 - NCT03801135 Slovenia;
Fingolimod
Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-JapicCTI-121961 -
Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS)
Teijin Pharma Limited
2014 Phase 3 JPRN-JapicCTI-142472 Japan;
2014 Phase 3 JPRN-JapicCTI-142471 Japan;
GILENYA 0,5 mg cápsulas duras
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Gammanorm
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark;
Gilenya
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
Group C meningococcal conjugate vaccine
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
H.P. Acthar® Gel
Mamatha Pasnoor, MD
2015 Phase 2 NCT02574962 United States;
HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
HIDROCLORURO DE FINGOLIMOD
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States;
HUMAN NORMAL IMMUNOGLOBULIN (IV)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark;
CSL Behring GmbH
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland;
2010 - EUCTR2009-017672-24-FI Finland;
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
Haemophilus type b vaccine (conjugated)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Hematopoietic stem cell transplantation
Northwestern University
2005 Phase 2 NCT00278629 United States;
Hizentra
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark;
2013 Phase 2 EUCTR2013-001428-20-DK Denmark;
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark;
CSL Behring
2022 - NCT04672733 France;
Hizentra®
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin (IVIg)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Human normal immunoglobulin (SCIg)
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin G (IgG > purity)
CSL Behring GmbH
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland;
2010 - EUCTR2009-017672-24-FI Finland;
Human normal immunoglobulin for intravenous administration
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
Human normal immunoglobulin for intravenous administrationn
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
Hyqvia
UMC Utrecht
2016 Phase 3 EUCTR2015-000828-28-NL Netherlands;
I10
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
I10E
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom;
IGIV,
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark;
IGVENA*FL 200ML 10G+SET
KEDRION
2007 - EUCTR2005-001136-76-IT Italy;
IMMUNOGLOBULIN G
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom;
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom;
IQYMUNE
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom;
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom;
IgPro10
CSL Behring
2019 Phase 4 NCT03684018 Canada;United States;
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
IgPro20
CSL Behring
2014 Phase 3 NCT02027701 Australia;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States;
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States;
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States;
IgPro20 (high dose)
CSL Behring
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
IgPro20 (low dose)
CSL Behring
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Immune Globulin IV (Human), Caprylate/Chromatography Purified
Grifols Therapeutics Inc.
2004 Phase 3 NCT00220740 Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States;
Immune Globulin Intravenous (human),
Baxalta now part of Shire
2008 Phase 3 NCT00666263 Canada;Denmark;Netherlands;Poland;United States;
Immune Globulin Intravenous Solution
Vera Bril
2017 Phase 3 NCT03166527 Canada;
Immune Globulin Subcutaneous (Human)
University of South Florida
2014 - NCT02465359 United States;
Immune globulin
National Center for Research Resources (NCRR)
1992 Phase 3 NCT00004772 -
Immunoadsorption
University of Ulm
2022 Phase 2 NCT04881682 Germany;
Immunoglobulin
University of Aarhus
2020 Phase 4 NCT04589299 Denmark;
Immunoglobulin perfusion
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France;
Immunoglobuline G
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic;
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine;
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania;
Immunoglobulins
Rigshospitalet, Denmark
2014 - NCT02111590 Denmark;
University of Ulm
2022 Phase 2 NCT04881682 Germany;
Immunoglobulins, normal human, for extravascular adm.
CSL Behring AG
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom;
Immunoglobulins, normal human, for intravascular adm.
KEDRION
2007 - EUCTR2005-001136-76-IT Italy;
Intratect
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Intravenous Immunoglobulin
University of Minnesota
2015 - NCT02414490 United States;
Intravenous immunoglobulin
University of Aarhus
2005 Phase 2 NCT00268788 Denmark;
Intravenous immunoglobulin (IVIg)
National Institute of Neurological Disorders and Stroke (NINDS)
1990 Phase 2 NCT00001287 United States;
J07AH07
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
KIOVIG
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom;
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom;
KIOVIG 100 mg/ml solution for infusion
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark;
Kiovig
Erasmus MC
2014 Phase 4 EUCTR2013-004988-32-NL Netherlands;
Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom;
Lipoic acid
Oregon Health and Science University
2009 Phase 2 NCT00962429 United States;
MABTHERA - 1 FIALA 500 MG 50 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
2018 Phase 2 EUCTR2018-001347-31-IT Italy;
MD1003
MedDay Pharmaceuticals SA
2016 Phase 2 NCT02967679 France;
Melphalan
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Menjugate
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Methylprednisolon (Solu-Medrol)
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;
Methylprednisolone
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom;
Methylprednisolone (Solu-Medrol)
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;
N. MENINGITIDIS GROUP C POLYSACCHARIDE
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
NPB-01
Nihon Pharmaceutical Co., Ltd
2013 Phase 3 NCT01827072 Japan;
2013 Phase 3 NCT01824251 Japan;
NewGam
Octapharma
2017 Phase 3 NCT02638207 Australia;Bulgaria;Canada;Czechia;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic;
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine;
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania;
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
PANZYGA
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine;
Panzyga
Octapharma
2022 Phase 3 NCT04929236 -
Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Placebo
Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-JapicCTI-121961 -
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Prednisolone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom;
Prednisone
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France;
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
Prevenar 13 sospensione per iniezione
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Privigen
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark;
2013 Phase 2 EUCTR2013-001428-20-DK Denmark;
Privigen®
CSL Behring GmbH
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland;
2010 - EUCTR2009-017672-24-FI Finland;
RHuPH20
UMC Utrecht
2016 - NCT02885259 Netherlands;
RVG 51680
Department of Neurology, Academic Medical Center
2014 - EUCTR2013-005363-52-NL Netherlands;
RVG 56083
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;
Recombinant human hyaluronidase
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 Japan;
Rituximab
Iijima Masahiro
2021 Phase 2 JPRN-jRCTs041210046 Japan;
2019 Phase 2 JPRN-jRCT2041180037 Japan;
Nagoya University Hospital
2019 Phase 2 JPRN-UMIN000035753 Japan;
University of Kansas Medical Center
2022 Phase 2 NCT04480450 -
Rituximab (genetical recombination)
Nagoya University
2019 Phase 2 NCT03864185 Japan;
Rozanolixizumab
UCB Biopharma S.P.R.L.
2019 Phase 2 NCT03861481 Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
UCB Biopharma SRL
2020 - NCT05014724 -
2019 Phase 2 NCT04051944 Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
SAR445088 (formerly BIVV020)
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-PL France;Germany;Italy;Netherlands;Poland;
SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
Sodium chloride
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom;
Subcutaneous immunoglobulin
University of Aarhus
2005 Phase 2 NCT00268788 Denmark;
Subcuvia
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark;
Johannes Jakobsen
2016 Phase 2 NCT02556437 Denmark;
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark;
Syngeneic Bone Marrow Transplantation
Fred Hutchinson Cancer Research Center
2008 Phase 2 NCT00716066 United States;
TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
TAK-771
Takeda
2021 Phase 3 NCT05084053 Japan;
TRIMETON - 10 MG/1 ML SOLUZIONE INIETTABILE 5 FIALE 1 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy;
UCB7665
UCB Biopharma SPRL
2020 Phase 2 EUCTR2018-004392-12-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2018-004392-12-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004392-12-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
UCB Biopharma SRL
2019 Phase 2 EUCTR2018-004392-12-BE Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2016-002411-17-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
VACCINO PNEUMOCOCCICO SACCARIDICO
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Vivaglobin
CSL Behring
2007 Phase 2 NCT00701662 Germany;Italy;Switzerland;United Kingdom;
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom;
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom;
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom;
intravenous immunoglobulin (IVIg)
University of Toronto
2015 Phase 4 NCT02372149 Canada;
liquid formulation of human immunoglobulin
CSL Behring
2010 Phase 3 NCT01184846 Belgium;Finland;France;Germany;Poland;